Skip to main content

Table 6 Correlation between NLR/CD34 and clinicopathological features in prostate cancer

From: Correlation between peripheral blood neutrophil-lymphocyte ratio and CD34 expression in prostate cancer

Patients and tumor characteristics NLR/CD34 Standard
Deviation
P-value
NLRLow/CD34Low NLRLow/CD34High NLRHigh/CD34Low NLRHigh/CD34High
PSA level (ng/ml)
  < 10 8 (42.1) 1 (5.3) 5 (26.3) 5 (26.3) 0.169 0.011
 10 ~ 20 10 (34.5) 6 (20.7) 4 (13.8) 9 (31.0) 0.142  
  > 20 3 (11.1) 4 (14.8) 6 (22.2) 14 (51.9) 0.050  
Gleason score
  ≤ 6 6 (42.9) 3 (21.4) 3 (21.4) 2 (14.3) 0.227 0.005
 7 11 (39.3) 2 (7.1) 8 (28.6) 7 (25.0) 0.161  
 8 ~ 10 4 (12.1) 6 (18.2) 4 (12.1) 19 (57.6) 0.059  
T stage
 T1–2 15 (45.5) 4 (12.1) 7 (21.2) 7 (21.2) 0.196 0.018
 T3–4 6 (14.3) 7 (16.7) 8 (19.0) 21 (50.0) 0.084  
Lymph node metastasis
 N0 18 (39.1) 8 (17.4) 11 (23.9) 9 (19.6) 0.201 0.011
 N1 3 (10.3) 3 (10.3) 4 (13.8) 19 (65.6) 0.173  
Distant metastasis
 M0 16 (37.2) 9 (20.9) 7 (16.3) 11 (25.6) 0.282 0.029
 M1 5 (15.6) 2 (6.3) 8 (25.0) 17 (53.1) 0.186  
TNM stage
 Stage II 19 (73.1) 2 (7.7) 2 (7.7) 3 (11.5) 0.195 0.000
 Stage III ~ IV 2 (4.1) 9 (18.4) 13 (26.5) 25 (51.0) 0.067  
  1. NLR neutrophil-to-lymphocyte ratio, PSA prostate specific antigen